Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
InQpharm Group clinical trials
The registry lists 29 studies whose lead sponsor is InQpharm Group. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 27, 2023.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to InQpharm Group.
- InQpharm Group29 studiesSame company
Something wrong?
Focus areas
Conditions InQpharm Group leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 29 of 29.
- Efficacy and Safety of Glucosanol™ in Body Weight ReductionCompletedNCT02930668Not applicable
- Benefit and Tolerability of IQP-LU-104 in Weight LossCompletedNCT03888911Not applicable
- Safety and Efficacy of IQP-MM-101 in Reducing Symptoms of DiarrhoeaCompletedNCT01969214Not applicable
- Efficacy and Safety of Litramine in 1 Year Weight Loss StudyCompletedNCT03227276Not applicable
- Vasoactive Effects of IQP-AS-118 in Healthy IndividualsWithdrawnNCT02871310Not applicable
- Tolerability and Benefit of IQP-AS-121 on Fatigue and Mental AlertnessWithdrawnNCT02871271Not applicable
- Benefit of IQP-AS-118 on Blood Pressure and LDL-cholesterolCompletedNCT02871362Not applicable
- Benefit and Tolerability of IQP-AE-103 in Weight LossCompletedNCT03058367Not applicable
- Efficacy and Safety of IQP-AK-102 in Reducing AppetiteCompletedNCT02774486Not applicable
- Benefit of IQP-AO-101 for SleepCompletedNCT03114696Not applicable
- Influence of IQPAS-119 on Post-Marathon Susceptibility to Infections and OthersCompletedNCT02873910Not applicable
- Clinical Benefit of a Mouthrinse for the Treatment of Dentine HypersensitivityCompletedNCT03232255Not applicable
- Efficacy of Glucosanol™ in Reducing Post-prandial Glucose Levels in Overweight SubjectsCompletedNCT02930681Not applicable
- Safety and Efficacy of IQP- AK-102 in Reducing Body WeightCompletedNCT01905956Phase 3
- Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract InfectionsTerminatedNCT01964885Phase 3
- Benefit of IQP-VV-102 in Reducing Postprandial Glucose Level in Overweight Caucasian SubjectsCompletedNCT02541344Phase 3
- Efficacy and Safety of IQP-VV-102 in Weight ManagementCompletedNCT01681069Phase 3
- Litramine for Weight LossCompletedNCT02488356Not applicable
- Litramine in Weight MaintenanceCompletedNCT01505387Phase 4
- Efficacy and Safety of Zenoctil in Reducing Body WeightCompletedNCT01423617Phase 3
- IQP-CL-101 in IBS ManagementCompletedNCT01774825Phase 3
- Safety and Efficacy of IQP-AK-102 in Reducing AppetiteCompletedNCT02041754Phase 3
- IQP-PO-101 for the Regulation of Bowel Movement FrequencyCompletedNCT01809587Phase 3
- Safety and Efficacy of Glucosanol in Reducing Body Weight in Overweight and Obese SubjectsCompletedNCT01407393Phase 4
- Safety and Efficacy of IQP-LH-101 in Postprandial HeartburnCompletedNCT01718639Phase 4
- Nasya in Allergic RhinitisCompletedNCT01503957Phase 3
- Effect of Litramine on Fat ExcretionCompletedNCT01590667Phase 4
- Efficacy and Safety of Glucosanol in Maintaining Body WeightCompletedNCT01435278Phase 4
- Safety and Efficacy of Litramine in Overweight and Obese SubjectsCompletedNCT01233349Phase 3